Full-Time

Raw Materials Director

Inorganics

Evonik

Evonik

10,001+ employees

Global specialty chemicals manufacturer and supplier

Compensation Overview

$123.5k - $223.6k/yr

Piscataway, NJ, USA + 2 more

More locations: Richmond, VA, USA | Allentown, PA, USA

In Person

Travel to supplier and plant locations, industry conferences, and other events is required as needed.

Bachelor's, MBA

Category
Operations & Logistics (1)
Required Skills
Microsoft Office
ERP
SAP Products
Excel/Numbers/Sheets

Get referred to Evonik

See people who can refer or advise you

Requirements
  • An undergraduate degree is required.
  • More than 10 years of procurement or related commercial experience is required.
  • Knowledge of the principles and practices of strategic sourcing and purchasing goods and services is required.
  • Broad functional and strong interpersonal skills, combined with strong negotiating and decision-making skills, are required.
  • Proficiency in building and maintaining business relationships, with strong verbal and written communication skills and the ability to rapidly understand complex structures, is required.
  • Ability to effectively plan and manage multiple tasks and initiatives simultaneously is required.
  • A strong work ethic and high level of integrity are required.
  • Knowledge of business law, contract preparation, accounting principles, ISO, and RC initiatives is required.
  • Proficiency in Microsoft Office applications, especially Excel, and demonstrated analytical skills are required.
  • Willingness to travel to Evonik suppliers and plant locations, industry conferences, and other events as required is required.
Responsibilities
  • Be accountable for sourcing a defined set of raw materials in North America.
  • Work with all stakeholders to develop sourcing strategies for key raw materials in alignment with Procurement and corporate goals; anticipate and manage sourcing barriers and issues, manage spend, and find savings.
  • Develop and support negotiation strategies and competence.
  • Maintain communication with key partners inside and outside the various Business Line organizations that consume the defined set of raw materials.
  • Understand and balance the interests, capabilities, and needs of operations and business management teams, Business Line supply chain teams, and Global Lead Buyers as stakeholders in product sourcing.
  • Create and implement formal written strategies for select high-impact raw materials in alignment with key internal stakeholders, focusing on medium- and long-term improvements.
  • Develop appropriate supply chain risk management strategies for all raw materials that address potential disruptions to operations and minimize risks while balancing expense and working capital management.
  • Identify and act on synergies with other Procurement Units within Evonik.
Desired Qualifications
  • A degree in Engineering or Chemistry disciplines is preferred.
  • An MBA or equivalent financial experience is preferred.
  • Business Line or commercial experience is preferred.
  • General ability to navigate within SAP or another enterprise resource planning system is preferred.

Evonik is a global specialty chemicals company that makes high-value ingredients used in everyday products, such as cars, footwear, and animal feed. Its products are designed to enhance performance by providing tailored chemical solutions across multiple industries and applications. Evonik operates in more than 100 countries, producing specialty chemicals through advanced formulations and manufacturing processes that meet specific customer needs. The company differentiates itself by its focused strategy on high-margin specialty chemicals after restructuring, its large, multinational manufacturing footprint, and ongoing efficiency-improvement efforts that paused major acquisitions through 2027 to prioritize internal transformation. The goal is to strengthen its leadership in specialty chemicals and sustain profitable growth by delivering specialized ingredients and performance materials while improving operational efficiency.

Company Size

10,001+

Company Stage

IPO

Headquarters

Essen, Germany

Founded

2007

Get referred to Evonik

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 adjusted EBITDA reached €630 million, and guidance rose to €2.0–€2.2 billion.
  • Evonik’s July 2026 Tippecanoe upgrade adds automation for higher-margin CDMO demand.
  • Chinese and Asian expansions in Nanjing and Leshan deepen growth exposure in 2026.

What critics are saying

  • Reuters on June 18, 2026 reported 3,200 more job cuts through 2029.
  • Evonik exits polyester in 2027 after failing to sell a €150m business.
  • If polyester and C4 exits fail, Evonik stays trapped in structurally low-return businesses.

What makes Evonik unique

  • Evonik’s 2026 methionine network spans Antwerp, Singapore, and Mobile, reducing supply shocks.
  • Its Tippecanoe API site and Nanjing amines plant anchor pharma and advanced materials.
  • Evonik licenses process technology, like Fuhua’s Leshan peroxide plant and AEM membranes.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Disability Insurance

Life Insurance

Parental Leave

Tuition Reimbursement

401(k) Retirement Plan

Health Savings Account/Flexible Spending Account

Paid Vacation

Flexible Work Hours

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

11%
Yahoo Finance
Aug 13th, 2026
Evonik's 24% Q2 EBITDA surge drives polymeric surfactants market to projected $17.8B by 2035

Evonik reported a 24% surge in Q2 EBITDA, while the global polymeric surfactants market is projected to reach $17.8 billion by 2035, according to a new report from ResearchAndMarkets.com. The market was valued at $10.5 billion in 2025 and is expected to grow at a 5.4% CAGR through 2035. Growth is driven by the transition towards water-based and low-VOC systems in coatings, paints, personal care, and industrial applications. Block copolymers held a 42.2% market share in 2025, making them the leading product category. Their dominance stems from precise molecular structure control and versatility across multiple applications including coatings, pharmaceuticals, agriculture, and personal care. The personal care and cosmetics industry represents a key growth area, fuelled by consumer demand for premium products offering improved texture and stability. Manufacturers are increasingly incorporating polymeric surfactants into product development as regulatory requirements and sustainability objectives evolve.

PR Newswire
Jul 8th, 2026
Evonik invests $100M to upgrade Indiana drug substance manufacturing facility

Evonik is investing $100 million over five years to modernise its drug substance manufacturing facility in Lafayette, Indiana. The investment will upgrade equipment including 100 m³ reactors, enhance automation, and improve efficiency at the site. The German chemicals company aims to meet growing demand for US-based contract development and manufacturing organisation services. The Tippecanoe facility is Evonik's second-largest US site and one of the world's largest active pharmaceutical ingredient facilities. The site features 170 m³ of high-potency API capacity, 860 m³ of reactor capacity for general APIs, and 2,500 m³ for large-scale fermentation. Evonik acquired the facility from Eli Lilly in 2010. The modernisation supports production of increasingly complex molecules for cancer, metabolic, and cardiovascular disease treatments whilst reducing greenhouse gas emissions.

AktienSensor
Jun 10th, 2026
Evonik shareholder raises $424M via convertible debt to fund R&D and bolster capital structure

Evonik Industries' principal shareholder, RAG-Stiftung, has issued €375 million in convertible debt maturing in December 2031. The note carries a 1.45% coupon and a conversion price of €19.46 per share, representing a 27% premium over the reference price at issuance. The transaction is part of RAG-Stiftung's long-term capital-raising framework, bringing its total outstanding convertible debt to approximately €1.4 billion. The low coupon reflects disciplined interest expense management in the specialty-chemicals sector. If converted, the debt would retire and dilute the foundation's equity stake by less than 1%. The proceeds will support research and development spending and provide a buffer against commodity price volatility. The German specialty-chemicals company faces competition from BASF, Lanxess and Solvay in high-performance polymers and advanced additives.

Yahoo Finance
Jun 10th, 2026
Evonik launches membrane to cut green hydrogen costs by 25%

German chemicals group Evonik has developed a membrane for electricity-based hydrogen production that could significantly reduce costs. Commercial manufacturing of the Anion Exchange Membrane (AEM) electrolysis system has begun at a pilot plant in Germany's Ruhr region. The technology uses fewer precious metals than traditional methods and allows hydrogen to be produced under pressure, eliminating additional compression steps. Specialist studies suggest the system could reduce investment costs by at least 25%. Green hydrogen currently costs two to four times more than grey hydrogen produced from natural gas. Evonik is targeting large-scale application in China, where it has established a technology centre in Shanghai to test the membranes under industrial conditions with local partners. The company expects strong demand growth for green hydrogen as industries transition to carbon neutrality.

AD HOC NEWS
Jun 3rd, 2026
Evonik shareholders approve $1.4B bond programme and capital increase to fund specialty chemicals shift

Evonik shareholders approved a €1.25 billion convertible bond programme and conditional capital increase of up to 37 million shares at the company's annual general meeting on Tuesday. The measures provide capital for acquisitions as the German chemicals group accelerates its shift toward higher-margin specialty products. The board also proposed a €1.00 per share dividend, totalling roughly €466 million. Deutsche Bank Research maintained its 'Hold' rating with a €16 price target, noting that a sale of Evonik's C4 chemicals unit is expected soon. Evonik shares have climbed 26% year-to-date, trading near €16.85, though technical indicators suggest overbought conditions. The company will report second-quarter results in August.